February 2022

In September 2021, the United States Food and Drug Administration (FDA) issued a draft guidance, “Real-Word Data: Assessing…

Atopic dermatitis (AD) is a chronic, relapsing inflammatory condition that is estimated to afflict more than 26 million people in…

In January 2022, the Congressional Budget Office (CBO) released a new report on prescription drugs, with a focus on nationwide…

On February 1, 2022, the United States Department of Justice (DOJ) announced the second-largest amount of False Claims Act…

On January 19, 2022, the United States Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) sent an…

Earlier this year, the United States Department of Health and Human Services (HHS) Office of the National Coordinator for Health…

In early February 2022, the Centers for Medicare and Medicaid Services (CMS) released its proposed payment policy changes for…

In an effort to educate clinicians and patients on the potential side effects of using Mycophenolate’s during pregnancy, …

Policy and Medicine Compliance Update is our monthly compliance publication designed to help compliance professionals go in depth…

A recent study funded by the Agency for Healthcare Research and Quality (AHRQ) used a novel team-based approach, Implementing…